EUVIMEDEUVIMED entdecken
Crossref

Delayed Survival Benefit of Enzalutamide Plus Radium‐223 in Metastatic Castration‐Resistant Prostate Cancer: A Time‐Dependent Analysis of Reconstructed Individual Patient Data From the PEACE ‐3 Trial

Wei Chen iD, Soichiro Yoshida iD, Shugo Yajima iD, Kenji Tanabe iD, Motohiro Fujiwara iD, Hiroshi Fukushima iD, Hajime Tanaka iD, Akihiro Hirakawa, Hitoshi Masuda, Yasuhisa Fujii iD

International Journal of Urology · 2026

DOI: 10.1111/iju.70376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Wei Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant, Radium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Sichuan Science and Technology Program, Health Commission of Sichuan Province Medical Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective The PEACE‐3 trial demonstrated overall survival benefit for enzalutamide plus radium‐223 versus enzalutamide alone in metastatic castration‐resistant prostate cancer (mCRPC), but survival curves showed initial crossing followed by progressive separation, indicating non‐proportional hazards. We aimed to characterize the time‐dependent treatment effects through comprehensive analysis.

Methods

Individual patient datas (IPD) were reconstructed from published Kaplan–Meier curves of the PEACE‐3 trial. Time‐dependent treatment effects were evaluated by restricted mean survival time (RMST) analysis at predefined time points (18–72 months), time‐dependent Cox regression with treatment‐by‐time interaction, piecewise Cox regression across 6 time intervals, landmark analyses, and Fleming‐Harrington weighted log‐rank tests.

Results

A total of 446 IPDs were reconstructed. Validation confirmed consistency with the original trial. During the initial 18 months, combination therapy showed no survival advantage (RMST difference: −0.36 months, 95% CI, −0.90 to 0.18, p = 0.20) and was associated with increased hazard (HR = 2.14, 95% CI, 1.48–3.10, p < 0.001). Significant survival benefits were observed after 60 months, with RMST differences of 4.34 months (95% CI, 0.49–8.19, p = 0.03) at 60 months and 6.25 months (95% CI, 1.56–10.95, p = 0.01) at 72 months. Time‐dependent Cox regression confirmed a significant treatment‐by‐time interaction ( p < 0.01). Piecewise analysis revealed the most substantial benefit for 60–72 months (HR = 0.20, 95% CI, 0.05–0.77, p = 0.02). Landmark analyses consistently demonstrated increasing treatment benefit with longer follow‐up.

Conclusions

Enzalutamide plus radium‐223 demonstrates delayed but substantial survival benefit in mCRPC, becoming statistically significant after 60 months with over 6 months survival advantage at 72 months. Registry and the Registration No. of the Study/Trial Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantRadiumAgedHumansMaleBenzamidesKaplan-Meier EstimateNitrilesTime FactorsRandomized Controlled Trials as TopicSecondary Data Analysis

Stichwörter der Autor:innen

enzalutamidemetastatic castration‐resistant prostate cancernon‐proportional hazardsradium‐223shiny method

Substanzen

BenzamidesenzalutamideNitrilesPhenylthiohydantoinRadiumRadium-223

Autor:innen und Institutionen

  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
  • Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Urology, Teikyo University Hospital, Kawasaki, Japan.
  • Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Wei Chen, Soichiro Yoshida, Shugo Yajima, Kenji Tanabe, Motohiro Fujiwara, Hiroshi Fukushima, Hajime Tanaka, Yasuhisa Fujii

Förderung

  • Sichuan Science and Technology Program
  • Health Commission of Sichuan Province Medical Science and Technology Program

Zitieren

APA

Chen, W., Yoshida, S., Yajima, S., Tanabe, K., Fujiwara, M., Fukushima, H., Tanaka, H., Hirakawa, A., Masuda, H., & Fujii, Y. (2026). Delayed Survival Benefit of Enzalutamide Plus Radium‐223 in Metastatic Castration‐Resistant Prostate Cancer: A Time‐Dependent Analysis of Reconstructed Individual Patient Data From the PEACE ‐3 Trial. International Journal of Urology. https://doi.org/10.1111/iju.70376

Vancouver

Chen W, Yoshida S, Yajima S, Tanabe K, Fujiwara M, Fukushima H, et al. Delayed Survival Benefit of Enzalutamide Plus Radium‐223 in Metastatic Castration‐Resistant Prostate Cancer: A Time‐Dependent Analysis of Reconstructed Individual Patient Data From the PEACE ‐3 Trial. International Journal of Urology. 2026. doi:10.1111/iju.70376

BibTeX
@article{Chen2026,
  author = {Chen, Wei and Yoshida, Soichiro and Yajima, Shugo and Tanabe, Kenji and Fujiwara, Motohiro and Fukushima, Hiroshi and Tanaka, Hajime and Hirakawa, Akihiro and Masuda, Hitoshi and Fujii, Yasuhisa},
  title = {Delayed Survival Benefit of Enzalutamide Plus Radium‐223 in Metastatic Castration‐Resistant Prostate Cancer: A Time‐Dependent Analysis of Reconstructed Individual Patient Data From the PEACE ‐3 Trial},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70376}
}
Kostenlos starten →